Nirmal Bang is bullish on Take Solutions and has recommended buy rating on the stock with a target of Rs 43 in its September 7, 2011 research report.
“Revenues from Supply Chain (SCM) Segment constitutes almost 49% to the revenues in FY11 of Take. Post WCI acquisition which is in Lifesciences, SCM contribution to revenues has come down to 44% in Q1FY12. 65% of the revenues in FY11 came from the US where Mr. Levey has wide exposure.”.... Nirmal Bang is bullish on Take Solutions and has recommended buy rating on the stock with a target of Rs 43 in its September 7, 2011 research report.
“Revenues from Supply Chain (SCM) Segment constitutes almost 49% to the revenues in FY11 of Take. Post WCI acquisition which is in Lifesciences, SCM contribution to revenues has come down to 44% in Q1FY12. 65% of the revenues in FY11 came from the US where Mr. Levey has wide exposure.”
“Considering huge focus in this segment, Mr Levey’s appointment would bring in a lot more visibility to the SCM business of the company. In addition, his contacts in this industry and geographical knowledge would aid in widening the client base. The company has given guidance of 6-7% QoQ growth for the next 2 to 3 quarters. EBIDTA margins are expected to move up in the range of 22-23% for the company.”
“Take solutions are operating in the non-BFSI segments of SCM and lifesciences where the effect of Global Crisis may not be tough. Post the latest development in the company,we find the stock very attractive which is trading at 4.5x FY12E EPS and recommend a BUY on the stock,” says Nirmal Bang research report
back
“Revenues from Supply Chain (SCM) Segment constitutes almost 49% to the revenues in FY11 of Take. Post WCI acquisition which is in Lifesciences, SCM contribution to revenues has come down to 44% in Q1FY12. 65% of the revenues in FY11 came from the US where Mr. Levey has wide exposure.”.... Nirmal Bang is bullish on Take Solutions and has recommended buy rating on the stock with a target of Rs 43 in its September 7, 2011 research report.
“Revenues from Supply Chain (SCM) Segment constitutes almost 49% to the revenues in FY11 of Take. Post WCI acquisition which is in Lifesciences, SCM contribution to revenues has come down to 44% in Q1FY12. 65% of the revenues in FY11 came from the US where Mr. Levey has wide exposure.”
“Considering huge focus in this segment, Mr Levey’s appointment would bring in a lot more visibility to the SCM business of the company. In addition, his contacts in this industry and geographical knowledge would aid in widening the client base. The company has given guidance of 6-7% QoQ growth for the next 2 to 3 quarters. EBIDTA margins are expected to move up in the range of 22-23% for the company.”
“Take solutions are operating in the non-BFSI segments of SCM and lifesciences where the effect of Global Crisis may not be tough. Post the latest development in the company,we find the stock very attractive which is trading at 4.5x FY12E EPS and recommend a BUY on the stock,” says Nirmal Bang research report